Scarica l'app Stockscreener
189.99
16.77%
27.28
Dopo l'orario di chiusura:
188.00
-1.99
-1.05%
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
Major Investment Alert: Adage Capital’s Bold Move in Praxis Precision Medicines! - TipRanks
Can Praxis Precision Medicines Keep Climbing? - timothysykes.com
Praxis Shares Skyrocket: Too Late to Buy? - StocksToTrade
Praxis Precision Medicines: A New High? - timothysykes.com
Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday - Benzinga
Praxis Precision (PRAX) Triples on Stellar Drug Trial Results - Insider Monkey
Boston biotech raises $525M after stock triples on late-stage drug trial results - The Business Journals
Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? - Yahoo Finance
Praxis Precision Medicines (PRAX) Stock Soars After Essential Tremor Drug Success - parameter.io
Praxis Precision Medicines, Inc. (PRAX) Stock: Soars 183% Following $525M Public Offering Announcement - parameter.io
HC Wainwright & Co. Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Deutsche Bank Boosts Price Target on Praxis Precision Medicines to $280 From $65, Keeps Buy Rating - MarketScreener
Praxis Precision Medicines extends rally after $525 mln stock sale - TradingView
Praxis: Back From The Dead, Ulixacaltamide Returns In Essential Tremor With Caveats (PRAX) - Seeking Alpha
Praxis Precision Medicines Reaches Analyst Target Price - Nasdaq
Praxis Precision Medicines prices $525 million public offering By Investing.com - Investing.com Nigeria
Why Praxis Precision Medicines Stock Skyrocketed - TipRanks
Praxis Precision Stock Extends Rally Premarket As Wall Street Turns Hyper-Bullish After Essential Tremor Trial Win - Stocktwits
Praxis Precision Medicines Prices $525 Million Share Offering - MarketScreener
Praxis Precision Medicines (PRAX) Aims to Raise $525M Through Pu - GuruFocus
Praxis Precision Medicines prices $525M public offering - MSN
A Look at Praxis Precision Medicines (PRAX) Valuation Following Positive Phase 3 Results in Essential Tremor - simplywall.st
Praxis Precision Medicines prices $525 million public offering - Investing.com
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering - Investing News Network
$525M Offering — Praxis Precision Medicines Prices Common Stock at $157 per Share - Stock Titan
Jefferies Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Praxis Precision Medicines stock hits 52-week high at 158.29 USD - Investing.com Philippines
Praxis Precision Medicines (PRAX) Stock Skyrockets 180% on Game‑Changing Trial – Analysts See 'Blockbuster' Upside - ts2.tech
Praxis Has Unexpected Hits In Two Phase II Essential Tremor Studies - insights.citeline.com
Praxis Precision (PRAX) Targets $400M Through Share and Warrant Sale - GuruFocus
Praxis Precision Medicines stock soars as Oppenheimer raises price target on trial success - Investing.com Nigeria
Praxis soars on essential tremor phase III, preps for NDA - BioWorld MedTech
Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing. - MSN
PRAX: Jefferies Analyst Significantly Raises Price Target to $300 | PRAX Stock News - GuruFocus
Praxis Precision (PRAX) Announces Public Offering of Common Stock - GuruFocus
Praxis Precision Medicines announces proposed public offering - Investing.com
Praxis Precision Medicines, Inc. Announces Proposed Public Offering - The Manila Times
TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More Movers - Barron's
Praxis Precision's Tremor-drug Trial Has Succeeded Where Others Have Failed. The Stock Is Skyrocketing. - 富途牛牛
Praxis Precision surges, analysts see ‘blockbuster potential’ for ulixacaltamide - Investing.com
Promising Potential of Praxis Precision Medicines: Buy Rating on Ulixacaltamide’s Strong Phase 3 Results and Market Opportunity - TipRanks
Praxis Precision Medicines’ Tremor Treatment is Back From the Dead. The Stock Is Up 200% - Barron's
Praxis Precision Medicines: Are Investors Betting Big? - timothysykes.com
Truist Securities raises Praxis Precision Medicines stock price target to $360 on positive trial results - Investing.com Canada
Praxis Precision Medicines stock price target raised to $251 by TD Cowen - Investing.com South Africa
Praxis Precision Medicine (PRAX): Analyst Raises Price Target by 212.5% | PRAX Stock News - GuruFocus
Truist Securities raises Praxis Precision Medicines stock price target to $360 on positive trial results By Investing.com - Investing.com Nigeria
Baird raises Praxis Precision Medicines stock price target to $275 on positive trial results - Investing.com
Guggenheim raises Praxis Precision Medicines stock price target to $350 on positive trial data By Investing.com - Investing.com South Africa
Praxis stock surges on late-stage trial win (PRAX:NASDAQ) - Seeking Alpha
Guggenheim raises Praxis Precision Medicines stock price target to $350 on positive trial data - Investing.com Canada
Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $300 - 富途牛牛
Trending Stocks Today | Praxis Precision Medicines Surges 213% - 富途牛牛
Optimistic Buy Rating for Praxis Precision Medicines Amid Positive Phase 3 Results and Strategic Advancements - TipRanks
A longshot bet on a tremor drug pays off - BioPharma Dive
The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 184% - inkl
This ‘Strong Buy’ Stock Has More Than Tripled Today. Should You Buy It Here? - Yahoo Finance
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):